PT-141 Peptide UAE: The Complete Guide to Bremelanotide

Reviewed by the CoreSup Research Team · Based on FDA clinical trial data, PubMed-indexed studies, and peer-reviewed pharmacology literature · Updated March 2026

PT-141 is unlike any other sexual health compound on the market. It doesn't work by increasing blood flow to your genitals, and it doesn't mimic hormones. Instead, it acts directly on receptors in your brain that govern sexual desire — which is why researchers have called it a breakthrough in a field that had been dominated by the same mechanism for two decades. In 2019, the FDA approved bremelanotide (the generic name for PT-141) under the brand name Vyleesi, making it the first as-needed treatment approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.

In the UAE, interest in PT-141 has grown significantly. The compound sits at the intersection of two realities: a population that's deeply health-conscious, and a culture that takes sexual wellness seriously. From Dubai to Abu Dhabi, both men and women are researching alternatives to conventional ED drugs and libido supplements — and PT-141 is consistently what they find when they go beyond the basics. Its mechanism is novel. Its clinical evidence is legitimate. And it works for both sexes, which is rare.

This guide covers everything a UAE resident needs to know about PT-141 — from its discovery and FDA approval to how it works at the receptor level, what you can realistically expect, and how it compares to Viagra and Cialis. Every claim in this article is backed by published research or official pharmacokinetic data.

TL;DR: PT-141 (bremelanotide) is a synthetic melanocortin peptide that increases sexual desire by activating MC3R and MC4R receptors in the brain — not through blood flow like Viagra. FDA-approved in 2019 as Vyleesi for HSDD in women, with Phase 3 RECONNECT trials (1,247 participants) showing statistically significant desire improvements vs placebo (P<0.001). The standard dose is 1.75 mg subcutaneous, 45 minutes before activity. Nausea affects ~40% of users.

Researching sexual health peptides? Browse the full PT-141 peptides range at CoreSup — research-grade compounds with third-party certificates of analysis, delivered across the UAE.

What Is PT-141 (Bremelanotide)?

PT-141 is the research name for bremelanotide — a synthetic, cyclic hepta-peptide analogue of alpha-melanocyte stimulating hormone (alpha-MSH). In plain terms: it's a small engineered protein that mimics a naturally occurring brain signalling molecule. Its formal chemical identity is a melanocortin receptor agonist, meaning it activates a specific family of receptors (the melanocortin receptors, or MCRs) found throughout the central nervous system.

Its origins are accidental in the best possible way. In the 1990s, researchers at the University of Arizona were developing Melanotan II — a synthetic analogue designed to induce tanning without UV exposure. During trials, participants reported something unexpected: spontaneous, prolonged sexual arousal. The tanning compound had an off-target effect on libido that nobody had anticipated. Researchers isolated and refined that effect, stripping back the tanning properties, and eventually produced PT-141 — a compound purpose-built for sexual function research.

PT-141 differs from Melanotan II in two important ways. First, it doesn't produce significant skin darkening — the MCR1 (melanocortin 1 receptor) activity that drives pigmentation was modified. Second, its half-life is shorter and its receptor selectivity is tighter, which makes its pharmacological profile cleaner and its side effects more predictable. Where Melanotan II is a blunt instrument, PT-141 is refined.

The compound is a 7-amino-acid cyclic peptide with the sequence cyclo-(Nle4,D-Phe7)-alpha-MSH(4-10). Molecular weight: 1025.2 Da. It's administered subcutaneously — either as a reconstituted lyophilised powder or as a pre-mixed injection pen (the Vyleesi format). Research use outside the FDA-approved context most commonly involves the powder form, reconstituted with bacteriostatic water.

How Does PT-141 Work? The Melanocortin Mechanism

PT-141 activates two specific receptors in the melanocortin family: MC3R (melanocortin 3 receptor) and MC4R (melanocortin 4 receptor). Both are expressed prominently in the hypothalamus — the brain region that regulates appetite, body temperature, and critically, sexual behaviour. This central mechanism is what sets PT-141 apart from every other sexual health compound that existed before it.

When PT-141 binds to MC4R in the hypothalamus, it triggers a cascade that ultimately increases dopaminergic activity in brain regions associated with reward and motivation. In practice, this means an increase in sexual desire at the level of the brain itself — not a mechanical increase in blood flow, not a hormonal spike, but an actual shift in how your central nervous system processes sexual motivation. The distinction matters enormously for understanding who benefits and why.

This is why PT-141 works for a subset of men who don't respond to sildenafil or tadalafil. PDE5 inhibitors require a baseline of sexual arousal to function — they amplify the physical response to desire. If the desire itself is absent or blunted (due to stress, psychological factors, or central nervous system dysregulation), PDE5 inhibitors may do nothing. PT-141 addresses the upstream problem: it doesn't amplify the response to desire, it generates the desire itself.

Pharmacokinetically, PT-141 reaches peak plasma concentration (T-max) at approximately one hour after subcutaneous injection (DrugBank, bremelanotide). The Cmax is 72.8 ng/mL at the 1.75 mg dose. Its half-life is approximately 2.7 hours. The FDA label specifies using it at least 45 minutes before anticipated activity, with effects typically perceived for 6–12 hours depending on individual metabolism.

MC3R vs MC4R: Why Both Matter

MC4R is the primary driver of PT-141's sexual effects — studies in animal models show that MC4R knockout eliminates the compound's pro-erectile and pro-desire activity. MC3R activation plays a supporting role in energy regulation and may contribute to the appetite-suppression some users notice as a secondary effect. Neither receptor is involved in blood pressure regulation at standard doses, which is why PT-141 doesn't carry the cardiovascular contraindications associated with PDE5 inhibitors and nitrates.

PT-141 vs Viagra and Cialis: A Different Kind of Sexual Health Compound

Comparing PT-141 to Viagra or Cialis is a category error — they don't compete because they don't work on the same problem. Sildenafil (Viagra) and tadalafil (Cialis) are PDE5 inhibitors: they block an enzyme that degrades cyclic GMP in penile smooth muscle, prolonging vasodilation and increasing blood flow. They're peripheral, mechanical, and response-dependent. PT-141 is central, neurochemical, and desire-generating. Understanding this distinction tells you exactly which compound belongs in which context.

The practical takeaway: if erection quality is the primary concern and desire is present, a PDE5 inhibitor is the simpler solution. If desire is absent, blunted, or if PDE5 inhibitors have stopped working, PT-141 addresses the upstream cause. For more information on how PT-141 performs specifically in men, see our dedicated guide on PT-141 for men and erectile dysfunction.

Who Uses PT-141? Men, Women, and Why

PT-141's user base is broader than most sexual health compounds because its mechanism isn't sex-specific. Both men and women have MC3R and MC4R receptors in their hypothalamus. Both sexes can experience central hypoactive desire. That's why the research spans both populations — and why the FDA approved it specifically for women while prior male-focused ED research continues.

Men with Erectile Dysfunction or Low Libido

Erectile dysfunction affects an estimated 150 million men globally, with projections reaching 322 million by 2025 (PubMed, 1999 projection study). For most men, PDE5 inhibitors remain first-line. But a meaningful subset — particularly older men, those with psychological contributors, or those on medications that reduce libido as a side effect — don't respond adequately. A 2004 double-blind study (PubMed 14963471) showed PT-141 produced statistically significant erectile responses vs placebo at doses above 7 mg intranasal, with onset of first erection at approximately 30 minutes. See the full PT-141 dosage guide for detailed protocol recommendations.

Women with HSDD

Hypoactive sexual desire disorder is one of the most prevalent female sexual dysfunctions, affecting an estimated 8–10% of premenopausal women globally. The RECONNECT Phase 3 trials enrolled 1,247 premenopausal women across two randomised, double-blind, 24-week studies. Bremelanotide produced statistically significant improvements in sexual desire scores and reductions in distress compared to placebo (P<0.001), which formed the basis of the 2019 FDA approval (PMC6819021). No equivalent pharmaceutical option existed before Vyleesi.

Couples Seeking Enhanced Intimacy

Beyond clinical populations, PT-141 sees significant interest among couples who want to synchronise desire — situations where one partner's libido has declined due to stress, hormonal shifts, or lifestyle factors. Unlike aphrodisiacs or testosterone boosters, PT-141 works acutely and on-demand, which means it can be planned around specific occasions without requiring daily supplementation or hormonal intervention.

What to Expect After Taking PT-141

Managing expectations is important with PT-141 — particularly for first-time users. The compound doesn't produce an immediate physical response the way a PDE5 inhibitor might. Instead, the effect is more subtle at onset and builds over 45–60 minutes. Most users describe it as an increasing awareness of and interest in sexual activity — a shift in mental focus rather than a sudden physical event.

The Timeline

After a subcutaneous injection, PT-141 is absorbed rapidly. Plasma concentration begins rising almost immediately and reaches T-max at approximately one hour (Drugs.com pharmacokinetics). The FDA label recommends administering at least 45 minutes before anticipated sexual activity. In practice, most users inject 60–90 minutes out to give the compound time to build and to allow any nausea — the most common side effect — to pass before the desired window.

Effects on desire and arousal typically persist for 6–12 hours. The physical effects in men (improved erectile function) generally track with the desire effects. In women, the experience is primarily psychological — an increase in receptivity and spontaneous desire rather than a physical sensation.

Dose-Response Relationship

First-time users frequently underdose and then conclude PT-141 doesn't work. The FDA-approved dose for Vyleesi is 1.75 mg. Research protocols for men have used a range from 1.25 mg to 4 mg. Starting at the lower end (1.25–1.5 mg) reduces nausea but may produce only subtle effects. The full 1.75 mg dose is where the RECONNECT trial data was generated. Exceeding 1.75 mg increases side effect frequency without proportionally increasing benefit based on available data.

What Doesn't Change

PT-141 doesn't affect blood pressure at standard doses (unlike nitrates). It doesn't alter testosterone levels. It doesn't cause sedation. It doesn't suppress endogenous hormonal production. Post-use, most users return to baseline within 12–24 hours with no notable withdrawal or rebound effects observed in clinical trials.

PT-141 Side Effects: What the Clinical Trial Data Actually Shows

The side effect profile of PT-141 is well-characterised because it went through a full FDA approval process. The RECONNECT Phase 3 trials involved 1,247 women over 24 weeks — giving us reliable frequency data that's rare in the peptide research space. The most common adverse events were: nausea (40.0% bremelanotide vs 1.3% placebo), flushing (20.3% vs 1.3%), headache (11.3% vs 1.9%), and injection site reactions (5.4% vs 0.5%) (Journals of Women's Health, 2022).

Nausea is the most frequently reported and the most commonly cited reason for discontinuation. It stems from MC1R activation — the same receptor pathway that drives the tanning effect in Melanotan II. Nausea typically peaks 30–60 minutes post-injection and resolves on its own within 1–2 hours in most cases. Three practical strategies reduce its impact significantly:

• Inject at night: If nausea peaks within an hour and you're using PT-141 in the evening, the worst of it often passes during sleep.
• Start lower: Beginning at 1 mg–1.25 mg and titrating up over several uses allows the body to adapt. Most users find nausea diminishes significantly after the first 2–3 uses.
• Pre-hydrate: Adequate water intake before injection reduces flushing and headache frequency noticeably.

Flushing (warmth, redness, tingling in the face or chest) is the second most common effect and is generally mild. It's also caused by MCR activation and tends to be brief. Headache mirrors what's seen with PDE5 inhibitors — likely vasodilatory in mechanism — and typically responds to standard analgesics if needed.

No serious cardiovascular events, hypotension episodes, or drug interactions with common medications were flagged in the RECONNECT data. However, the FDA label notes PT-141 causes a transient, dose-dependent decrease in blood pressure (mean systolic decrease of 6 mmHg at 1.75 mg). Individuals already on antihypertensive medications should consult a physician before use.

Is PT-141 Available in the UAE? What Dubai Residents Need to Know

PT-141 is not approved by UAE regulatory bodies (MOHAP or Dubai Health Authority) for therapeutic human use. Like most research peptides in the region, it exists in a regulatory grey area — it's neither explicitly banned as a controlled narcotic nor approved as a licensed pharmaceutical. The compound is available for research purposes through specialist suppliers, and CoreSup is among the few UAE-based vendors offering it with third-party certificates of analysis (CoA) and transparent lab testing documentation.

Quality matters significantly with peptides. The potency and purity of PT-141 sourced without CoA verification can vary widely. A compound that's 60% pure at 5 mg/vial delivers a meaningfully different experience (and different side effect profile) than a research-grade product at 98%+ purity. When CoreSup supplies PT-141, each batch comes with HPLC purity documentation — the same standard used in pharmaceutical development.

For UAE residents considering PT-141 research, the most important steps are: verify the supplier's CoA documentation, understand that the compound is for research purposes only, and consult a licensed physician who is familiar with peptide research if you have any pre-existing cardiovascular or hormonal conditions. Delivery to Dubai, Abu Dhabi, Sharjah, and across the Emirates is available through CoreSup's UAE shipping.

Questions about regulations, sourcing, and quality standards? The CoreSup FAQ page covers the most common queries from UAE customers.

Frequently Asked Questions About PT-141

Shop Featured Products

PT-141 Spray 10 mg

Buy Now

PT-141 10 mg

Buy Now